API | blonanserin

blonanserin (Lonasen) Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Blonanserin, sold under the brand name Lonasen, is a relatively new atypical antipsychotic commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As with many second-generation (atypical) antipsychotics it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics such as haloperidol. ^Wikipedia

Chemistry

SMILES: CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1
InChIKey: XVGOZDAJGBALKS-UHFFFAOYSA-N
Mol. Mass: 367.51
ALogP: 4.69 Partition coefficient
ChEMBL Molecule:
blonanserin

More Chemistry

Pharmacology

Mechanisms of Action:
- D(2) dopamine receptor (Homo sapiens) ^UniProt
- D(2) dopamine receptor (Chlorocebus aethiops) ^UniProt
- D(3) dopamine receptor (Homo sapiens) ^UniProt
- D(3) dopamine receptor (Chlorocebus aethiops) ^UniProt
- 5-hydroxytryptamine receptor 2A (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Oral
Pro Drug: No

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (1)

Schizophrenia

Experimental Indications - Clinical Trial Phases 1-4 (4)

Antipsychotic Agents (Phase 4)

Cognition Disorders (Phase 4)

Psychosocial Functioning (Phase 4)

Schizophrenia (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 4
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue